{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T18:57:23Z","timestamp":1789153043447,"version":"build-2803163510"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T00:00:00Z","timestamp":1728000000000},"content-version":"am","delay-in-days":369,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1S10OD023611"],"award-info":[{"award-number":["1S10OD023611"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 HL141934"],"award-info":[{"award-number":["R01 HL141934"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32-HL069768"],"award-info":[{"award-number":["T32-HL069768"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000008","name":"David and Lucile Packard Foundation","doi-asserted-by":"publisher","award":["2013-39274"],"award-info":[{"award-number":["2013-39274"]}],"id":[{"id":"10.13039\/100000008","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30-CA016086"],"award-info":[{"award-number":["P30-CA016086"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006808","name":"University of North Carolina","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006808","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009744","name":"University of North Carolina Eshelman Institute for Innovation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009744","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Biomaterialia"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.actbio.2023.08.052","type":"journal-article","created":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T21:23:37Z","timestamp":1693517017000},"page":"250-259","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Pegloticase co-administered with high MW polyethylene glycol effectively reduces PEG-immunogenicity and restores prolonged circulation in mouse"],"prefix":"10.1016","volume":"170","author":[{"given":"Zhongbo","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Limei","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4647-3239","authenticated-orcid":false,"given":"Alice","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6296-6754","authenticated-orcid":false,"given":"Anne","family":"Talkington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zibo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew C.","family":"Nyborg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Scott","family":"Bowers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7521-241X","authenticated-orcid":false,"given":"Brian","family":"LaMoreaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric W.","family":"Livingston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan E.","family":"Frank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel K.","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.actbio.2023.08.052_bib0001","doi-asserted-by":"crossref","first-page":"14022","DOI":"10.1021\/acsnano.1c05922","article-title":"Polyethylene glycol immunogenicity: theoretical, clinical, and practical aspects of anti-polyethylene glycol antibodies","volume":"15","author":"Chen","year":"2021","journal-title":"ACS Nano"},{"issue":"1","key":"10.1016\/j.actbio.2023.08.052_bib0002","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/0014-5793(90)81016-H","article-title":"Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes","volume":"268","author":"Klibanov","year":"1990","journal-title":"FEBS Lett."},{"issue":"21","key":"10.1016\/j.actbio.2023.08.052_bib0003","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S1359-6446(05)03575-0","article-title":"PEGylation, successful approach to drug delivery","volume":"10","author":"Veronese","year":"2005","journal-title":"Drug Discov. Today"},{"issue":"11","key":"10.1016\/j.actbio.2023.08.052_bib0004","doi-asserted-by":"crossref","first-page":"15723","DOI":"10.1021\/acsnano.0c06679","article-title":"Person-specific biomolecular coronas modulate nanoparticle interactions with immune cells in human blood","volume":"14","author":"Ju","year":"2020","journal-title":"ACS Nano"},{"issue":"5","key":"10.1016\/j.actbio.2023.08.052_bib0005","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1002\/wnan.1339","article-title":"Anti-PEG immunity: emergence, characteristics, and unaddressed questions","volume":"7","author":"Yang","year":"2015","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"issue":"2","key":"10.1016\/j.actbio.2023.08.052_bib0006","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1159\/000233309","article-title":"Antibodies against polyethylene glycol produced in animals by immunization with monomethoxy polyethylene glycol modified proteins","volume":"70","author":"Richter","year":"1983","journal-title":"Int. Arch. Allergy Appl. Immunol."},{"issue":"8","key":"10.1016\/j.actbio.2023.08.052_bib0007","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1248\/bpb.b12-00276","article-title":"Intravenous administration of polyethylene glycol-coated (PEGylated) proteins and PEGylated adenovirus elicits an anti-PEG immunoglobulin M response","volume":"35","author":"Shimizu","year":"2012","journal-title":"Biol. Pharm. Bull."},{"issue":"2","key":"10.1016\/j.actbio.2023.08.052_bib0008","doi-asserted-by":"crossref","first-page":"R60","DOI":"10.1186\/ar4497","article-title":"Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout","volume":"16","author":"Lipsky","year":"2014","journal-title":"Arthritis Res. Ther."},{"issue":"23","key":"10.1016\/j.actbio.2023.08.052_bib0009","doi-asserted-by":"crossref","first-page":"11804","DOI":"10.1021\/acs.analchem.6b03437","article-title":"Analysis of pre-existing IgG and IgM antibodies against polyethylene glycol (PEG) in the general population","volume":"88","author":"Yang","year":"2016","journal-title":"Anal. Chem."},{"issue":"1","key":"10.1016\/j.actbio.2023.08.052_bib0010","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3324\/haematol.2020.258525","article-title":"Pre-existing antibodies against polyethylene glycol reduce asparaginase activities on first administration of pegylated E. coli asparaginase in children with acute lymphocytic leukemia","volume":"107","author":"Khalil","year":"2022","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.actbio.2023.08.052_bib0011","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/cncr.22739","article-title":"Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients","volume":"110","author":"Armstrong","year":"2007","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.actbio.2023.08.052_bib0012","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1016\/j.jaci.2015.10.034","article-title":"Pre-existing anti-polyethylene glycol antibody linked to first-exposure allergic reactions to pegnivacogin, a PEGylated RNA aptamer","volume":"137","author":"Ganson","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"issue":"7","key":"10.1016\/j.actbio.2023.08.052_bib0013","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1001\/jama.2011.1169","article-title":"Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials","volume":"306","author":"Sundy","year":"2011","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.actbio.2023.08.052_bib0014","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1186\/ar4500","article-title":"Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients","volume":"16","author":"Hershfield","year":"2014","journal-title":"Arthritis Res. Ther."},{"issue":"2","key":"10.1016\/j.actbio.2023.08.052_bib0015","doi-asserted-by":"crossref","DOI":"10.3390\/polym12020298","article-title":"The importance of poly(ethylene glycol) alternatives for overcoming PEG immunogenicity in drug delivery and bioconjugation","volume":"12","author":"Hoang Thi","year":"2020","journal-title":"Polymers"},{"issue":"22","key":"10.1016\/j.actbio.2023.08.052_bib0016","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1002\/cmdc.201600374","article-title":"Half-life extension of biopharmaceuticals using chemical methods: alternatives to PEGylation","volume":"11","author":"van Witteloostuijn","year":"2016","journal-title":"ChemMedChem"},{"key":"10.1016\/j.actbio.2023.08.052_bib0017","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.cbpa.2015.08.009","article-title":"Protein-polymer conjugation-moving beyond PEGylation","volume":"28","author":"Qi","year":"2015","journal-title":"Curr. Opin. Chem. Biol."},{"issue":"45","key":"10.1016\/j.actbio.2023.08.052_bib0018","doi-asserted-by":"crossref","first-page":"8561","DOI":"10.1039\/C8SC01777H","article-title":"Zwitterlation mitigates protein bioactivity loss in vitro over PEGylation","volume":"9","author":"Han","year":"2018","journal-title":"Chem. Sci."},{"issue":"26","key":"10.1016\/j.actbio.2023.08.052_bib0019","doi-asserted-by":"crossref","first-page":"7743","DOI":"10.1002\/anie.201802452","article-title":"Polypeptides with high zwitterion density for safe and effective therapeutics","volume":"57","author":"Zhang","year":"2018","journal-title":"Angew. Chem. Int. Ed Engl."},{"issue":"5","key":"10.1016\/j.actbio.2023.08.052_bib0020","doi-asserted-by":"crossref","first-page":"767","DOI":"10.3899\/jrheum.200460","article-title":"Pegloticase in combination with methotrexate in patients with uncontrolled gout: a multicenter, open-label study (MIRROR)","volume":"48","author":"Botson","year":"2021","journal-title":"J. Rheumatol."},{"issue":"10","key":"10.1016\/j.actbio.2023.08.052_bib0021","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1016\/j.transproceed.2018.03.010","article-title":"A case report of immunosuppressant medicationassociated polyarticular tophaceous gout successfully treated using the polyethylene glycolconjugated uricase enzyme pegloticase","volume":"50","author":"Freyne","year":"2018","journal-title":"Transplant. Proc."},{"issue":"8","key":"10.1016\/j.actbio.2023.08.052_bib0022","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1002\/art.41731","article-title":"Reducing immunogenicity of pegloticase with concomitant use of mycophenolate mofetil in patients with refractory gout: a phase II, randomized, double-blind, placebo-controlled trial","volume":"73","author":"Khanna","year":"2021","journal-title":"Arthritis Rheumatol."},{"issue":"1","key":"10.1016\/j.actbio.2023.08.052_bib0023","doi-asserted-by":"crossref","first-page":"e129","DOI":"10.1097\/RHU.0000000000001639","article-title":"Pretreatment and coadministration with methotrexate improved durability of pegloticase response: an observational, proof-of-concept case series","volume":"28","author":"Botson","year":"2022","journal-title":"J. Clin. Rheumatol."},{"key":"10.1016\/j.actbio.2023.08.052_bib0024","series-title":"FDA Approves KRYSTEXXA\u00ae (pegloticase) Injection Co-Administered with Methotrexate","year":"2022"},{"key":"10.1016\/j.actbio.2023.08.052_bib0025","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.jconrel.2021.08.051","article-title":"High MW polyethylene glycol prolongs circulation of pegloticase in mice with anti-PEG antibodies","volume":"338","author":"Talkington","year":"2021","journal-title":"J. Control Release"},{"issue":"4","key":"10.1016\/j.actbio.2023.08.052_bib0026","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/nprot.2010.13","article-title":"Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine","volume":"5","author":"Vosjan","year":"2010","journal-title":"Nat. Protoc."},{"issue":"7","key":"10.1016\/j.actbio.2023.08.052_bib0027","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1023\/A:1018943613122","article-title":"Physiological parameters in laboratory animals and humans","volume":"10","author":"Davies","year":"1993","journal-title":"Pharm. Res."},{"issue":"4","key":"10.1016\/j.actbio.2023.08.052_bib0028","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1177\/074823379701300401","article-title":"Physiological parameter values for physiologically based pharmacokinetic models","volume":"13","author":"Brown","year":"1997","journal-title":"Toxicol. Ind. Health"},{"issue":"1","key":"10.1016\/j.actbio.2023.08.052_bib0029","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3181\/00379727-75-18083","article-title":"Plasma and blood volumes of mouse organs, as determined with radioactive iodoproteins","volume":"75","author":"Kaliss","year":"1950","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"10.1016\/j.actbio.2023.08.052_bib0030","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.3389\/fimmu.2019.02630","article-title":"Molecular design, optimization, and genomic integration of chimeric b cell receptors in murine B cells","volume":"10","author":"Pesch","year":"2019","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.actbio.2023.08.052_bib0031","doi-asserted-by":"crossref","first-page":"e68758","DOI":"10.1371\/journal.pone.0068758","article-title":"A cleavable N-terminal signal peptide promotes widespread olfactory receptor surface expression in HEK293T cells","volume":"8","author":"Shepard","year":"2013","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.actbio.2023.08.052_bib0032","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/s41565-020-00813-z","article-title":"DNA scaffolds enable efficient and tunable functionalization of biomaterials for immune cell modulation","volume":"16","author":"Huang","year":"2021","journal-title":"Nat. Nanotechnol."},{"issue":"Pt B","key":"10.1016\/j.actbio.2023.08.052_bib0033","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jconrel.2016.06.040","article-title":"Anti-PEG antibodies in the clinic: current issues and beyond PEGylation","volume":"244","author":"Zhang","year":"2016","journal-title":"J. Control Release"},{"issue":"1","key":"10.1016\/j.actbio.2023.08.052_bib0034","doi-asserted-by":"crossref","first-page":"R12","DOI":"10.1186\/ar1861","article-title":"Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase","volume":"8","author":"Ganson","year":"2006","journal-title":"Arthritis Res. Ther."},{"issue":"3","key":"10.1016\/j.actbio.2023.08.052_bib0035","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/art.22403","article-title":"Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout","volume":"56","author":"Sundy","year":"2007","journal-title":"Arthritis Rheum."},{"issue":"36","key":"10.1016\/j.actbio.2023.08.052_bib0036","doi-asserted-by":"crossref","first-page":"6288","DOI":"10.1002\/anie.200902672","article-title":"Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives","volume":"49","author":"Knop","year":"2010","journal-title":"Angew. Chem. Int. Ed Engl."},{"issue":"Pt A","key":"10.1016\/j.actbio.2023.08.052_bib0037","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.addr.2015.09.012","article-title":"PEGylation as a strategy for improving nanoparticle-based drug and gene delivery","volume":"99","author":"Suk","year":"2016","journal-title":"Adv. Drug. Deliv. Rev."},{"issue":"1","key":"10.1016\/j.actbio.2023.08.052_bib0038","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines9010065","article-title":"Nanomaterial delivery systems for mRNA vaccines","volume":"9","author":"Buschmann","year":"2021","journal-title":"Vaccines"},{"key":"10.1016\/j.actbio.2023.08.052_bib0039","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.addr.2020.12.014","article-title":"Self-assembled mRNA vaccines","volume":"170","author":"Kim","year":"2021","journal-title":"Adv. Drug. Deliv. Rev."},{"issue":"9","key":"10.1016\/j.actbio.2023.08.052_bib0040","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.3748\/wjg.v21.i9.2826","article-title":"Protracted anaphylaxis developed after peginterferon alpha-2a administration for chronic hepatitis C","volume":"21","author":"Sakatani","year":"2015","journal-title":"World J. Gastroenterol."},{"issue":"4","key":"10.1016\/j.actbio.2023.08.052_bib0041","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s40272-015-0129-1","article-title":"Allergic reactions associated with intravenous versus intramuscular pegaspargase: a retrospective chart review","volume":"17","author":"Abbott","year":"2015","journal-title":"Paediatr. Drugs"},{"key":"10.1016\/j.actbio.2023.08.052_bib0042","doi-asserted-by":"crossref","DOI":"10.3389\/falgy.2021.715844","article-title":"Anaphylaxis to Pfizer\/BioNTech mRNA COVID-19 vaccine in a patient with clinically confirmed PEG allergy","volume":"2","author":"McSweeney","year":"2021","journal-title":"Front Allergy"},{"issue":"11","key":"10.1016\/j.actbio.2023.08.052_bib0043","doi-asserted-by":"crossref","first-page":"e29295","DOI":"10.1002\/pbc.29295","article-title":"Safety of administration of BNT162b2 mRNA (Pfizer-BioNTech) COVID-19 vaccine in youths and young adults with a history of acute lymphoblastic leukemia and allergy to PEG-asparaginase","volume":"68","author":"Mark","year":"2021","journal-title":"Pediatr. Blood. Cancer"},{"issue":"6","key":"10.1016\/j.actbio.2023.08.052_bib0044","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1177\/1078155214542493","article-title":"Delayed hypersensitivity reaction related to the use of pegfilgrastim","volume":"21","author":"Dadla","year":"2015","journal-title":"J. Oncol. Pharm. Pract."},{"issue":"4","key":"10.1016\/j.actbio.2023.08.052_bib0045","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/j.jaip.2020.12.047","article-title":"mRNA vaccines to prevent COVID-19 disease and reported allergic reactions: current evidence and suggested approach","volume":"9","author":"Banerji","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"issue":"6","key":"10.1016\/j.actbio.2023.08.052_bib0046","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1016\/j.jaci.2016.04.058","article-title":"Pre-existing anti-PEG antibodies are associated with severe immediate allergic reactions to pegnivacogin, a PEGylated aptamer","volume":"138","author":"Povsic","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.actbio.2023.08.052_bib0047","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jconrel.2014.08.009","article-title":"Features of complement activation-related pseudoallergy to liposomes with different surface charge and PEGylation: comparison of the porcine and rat responses","volume":"195","author":"Dezsi","year":"2014","journal-title":"J. Control Release"},{"issue":"4","key":"10.1016\/j.actbio.2023.08.052_bib0048","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/j.jaip.2020.11.011","article-title":"Anti-PEG IgE in anaphylaxis associated with polyethylene glycol","volume":"9","author":"Zhou","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"issue":"8","key":"10.1016\/j.actbio.2023.08.052_bib0049","doi-asserted-by":"crossref","first-page":"9315","DOI":"10.1021\/acsnano.9b03942","article-title":"Pseudo-anaphylaxis to Polyethylene Glycol (PEG)-coated liposomes: roles of anti-PEG IgM and complement activation in a porcine model of human infusion reactions","volume":"13","author":"Kozma","year":"2019","journal-title":"ACS Nano"},{"issue":"8","key":"10.1016\/j.actbio.2023.08.052_bib0050","doi-asserted-by":"crossref","first-page":"11769","DOI":"10.1021\/acsnano.2c04543","article-title":"Anti-PEG antibodies boosted in humans by SARS-CoV-2 lipid nanoparticle mRNA vaccine","volume":"16","author":"Ju","year":"2022","journal-title":"ACS Nano"},{"issue":"42","key":"10.1016\/j.actbio.2023.08.052_bib0051","doi-asserted-by":"crossref","first-page":"6114","DOI":"10.1016\/j.vaccine.2022.08.024","article-title":"mRNA-1273 but not BNT162b2 induces antibodies against polyethylene glycol (PEG) contained in mRNA-based vaccine formulations","volume":"40","author":"Carreno","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.actbio.2023.08.052_bib0052","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jconrel.2022.12.039","article-title":"Anti-PEG antibodies before and after a first dose of Comirnaty\u00ae (mRNA-LNP-based SARS-CoV-2 vaccine)","volume":"354","author":"Bavli","year":"2023","journal-title":"J. Control Release"},{"issue":"3","key":"10.1016\/j.actbio.2023.08.052_bib0053","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41577-022-00825-x","article-title":"Impact of anti-PEG antibodies induced by SARS-CoV-2 mRNA vaccines","volume":"23","author":"Ju","year":"2023","journal-title":"Nat. Rev. Immunol."},{"issue":"40","key":"10.1016\/j.actbio.2023.08.052_bib0054","doi-asserted-by":"crossref","first-page":"18419","DOI":"10.1021\/jacs.2c06877","article-title":"Engineering poly(ethylene glycol) nanoparticles for accelerated blood clearance inhibition and targeted drug delivery","volume":"144","author":"Tian","year":"2022","journal-title":"J. Amer. Chem. Soc."},{"key":"10.1016\/j.actbio.2023.08.052_bib0055","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jconrel.2019.08.017","article-title":"Overcoming anti-PEG antibody mediated accelerated blood clearance of PEGylated liposomes by pre-infusion with high molecular weight free PEG","author":"McSweeney","year":"2019","journal-title":"J. Control Release"},{"issue":"7","key":"10.1016\/j.actbio.2023.08.052_bib0056","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1021\/acs.molpharmaceut.5b00144","article-title":"Anti-PEG IgM is a major contributor to the accelerated blood clearance of polyethylene glycol-conjugated protein","volume":"12","author":"Mima","year":"2015","journal-title":"Mol. Pharmac."},{"issue":"1","key":"10.1016\/j.actbio.2023.08.052_bib0057","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/hae.12762","article-title":"Safety of PEGylated recombinant human full-length coagulation factor VIII (BAX 855) in the overall context of PEG and PEG conjugates","volume":"22","author":"Stidl","year":"2016","journal-title":"Haemophilia"},{"key":"10.1016\/j.actbio.2023.08.052_bib0058","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/978-1-4939-8796-2_16","article-title":"Safety and toxicity of recombinant methioninase and polyethylene glycol (PEG) recombinant methioninase in primates","volume":"1866","author":"Hoffman","year":"2019","journal-title":"Methods Mol. Biol."},{"issue":"1","key":"10.1016\/j.actbio.2023.08.052_bib0059","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1124\/dmd.106.012419","article-title":"PEGylated proteins: evaluation of their safety in the absence of definitive metabolism studies","volume":"35","author":"Webster","year":"2007","journal-title":"Drug Metab. Dispos."},{"issue":"6","key":"10.1016\/j.actbio.2023.08.052_bib0060","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.semarthrit.2016.09.007","article-title":"Pegloticase failure and a possible solution: immunosuppression to prevent intolerance and inefficacy in patients with gout","volume":"46","author":"Berhanu","year":"2017","journal-title":"Semin. Arthritis Rheum."},{"issue":"1","key":"10.1016\/j.actbio.2023.08.052_bib0061","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.semarthrit.2018.11.006","article-title":"Recapture and improved outcome of pegloticase response with methotrexate-a report of two cases and review of the literature","volume":"49","author":"Bessen","year":"2019","journal-title":"Semin. Arthritis Rheum."}],"container-title":["Acta Biomaterialia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1742706123005160?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1742706123005160?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T18:09:22Z","timestamp":1761674962000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1742706123005160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":61,"alternative-id":["S1742706123005160"],"URL":"https:\/\/doi.org\/10.1016\/j.actbio.2023.08.052","relation":{},"ISSN":["1742-7061"],"issn-type":[{"value":"1742-7061","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pegloticase co-administered with high MW polyethylene glycol effectively reduces PEG-immunogenicity and restores prolonged circulation in mouse","name":"articletitle","label":"Article Title"},{"value":"Acta Biomaterialia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.actbio.2023.08.052","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}